Pharmacyte Biotech Stock Short Ratio
| PMCB Stock | USD 2.13 0.09 4.05% |
PharmaCyte Biotech fundamentals help investors to digest information that contributes to PharmaCyte Biotech's financial success or failures. It also enables traders to predict the movement of PharmaCyte Stock. The fundamental analysis module provides a way to measure PharmaCyte Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PharmaCyte Biotech stock.
PharmaCyte |
PharmaCyte Biotech Company Short Ratio Analysis
PharmaCyte Biotech's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current PharmaCyte Biotech Short Ratio | 0.98 X |
Most of PharmaCyte Biotech's fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PharmaCyte Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, PharmaCyte Biotech has a Short Ratio of 0.98 times. This is 74.87% lower than that of the Biotechnology sector and 86.77% lower than that of the Health Care industry. The short ratio for all United States stocks is 75.5% higher than that of the company.
PharmaCyte Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PharmaCyte Biotech's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PharmaCyte Biotech could also be used in its relative valuation, which is a method of valuing PharmaCyte Biotech by comparing valuation metrics of similar companies.PharmaCyte Biotech is currently under evaluation in short ratio category among related companies.
PharmaCyte Fundamentals
| Return On Equity | -0.0174 | ||||
| Return On Asset | -0.0524 | ||||
| Current Valuation | (19.61 M) | ||||
| Shares Outstanding | 8.45 M | ||||
| Shares Owned By Insiders | 8.11 % | ||||
| Shares Owned By Institutions | 15.05 % | ||||
| Number Of Shares Shorted | 45.73 K | ||||
| Price To Earning | 9.57 X | ||||
| Price To Book | 0.60 X | ||||
| EBITDA | (4.32 M) | ||||
| Net Income | (4.32 M) | ||||
| Cash And Equivalents | 82.23 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 3.34 K | ||||
| Current Ratio | 75.51 X | ||||
| Book Value Per Share | 3.68 X | ||||
| Cash Flow From Operations | (3.79 M) | ||||
| Short Ratio | 0.98 X | ||||
| Earnings Per Share | (1.48) X | ||||
| Beta | -0.16 | ||||
| Market Capitalization | 18.77 M | ||||
| Total Asset | 73.28 M | ||||
| Retained Earnings | (115.96 M) | ||||
| Working Capital | 67.56 M | ||||
| Current Asset | 1.6 M | ||||
| Current Liabilities | 449 K | ||||
| Net Asset | 73.28 M |
About PharmaCyte Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PharmaCyte Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PharmaCyte Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PharmaCyte Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PharmaCyte Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out PharmaCyte Biotech Piotroski F Score and PharmaCyte Biotech Altman Z Score analysis. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.Note that the PharmaCyte Biotech information on this page should be used as a complementary analysis to other PharmaCyte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is PharmaCyte Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.